ascopubs.org

Bcr-Abl mutations in imatinib-resistant CML and Ph+ALL patients (pts) enrolled in a phase I study of AMN107

Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: Results of the CA180005 ’START-A’ study This is an ASCO Meeting Abstract ...
ascopubs.org

BCR-ABL transcript analysis of patients (pts) with imatinib-resistant or -intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.

Phase II study of decitabine and gemtuzumab ozogamicin (GO) in acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Background: CML patients with different types of BCR-ABL ...
Medical Xpress

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Gleevec, a cancer drug first approved for sale in 2001, has dramatically changed the lives of people with chronic myeloid leukemia. This form of cancer was once regarded as very difficult to combat, ...
Medscape

How Does the History of Chronic Myeloid Leukemia Inform the Future of Diagnosis, Treatment, Resistance, and Cure?

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Michael J. Mauro, ...